Analyst Price Targets — LNTH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 15, 2026 12:37 pm | Richard Newitter | Truist Financial | $98.00 | $82.68 | TheFly | Lantheus price target raised to $98 from $89 at Truist |
| April 13, 2026 2:42 pm | Anthony Petrone | Mizuho Securities | $95.00 | $80.50 | TheFly | Lantheus price target raised to $95 from $85 at Mizuho |
| March 17, 2026 7:08 pm | Matthew Taylor | Jefferies | $110.00 | $80.45 | StreetInsider | Lantheus Holdings (LNTH) PT Raised to $110 at Jefferies |
| February 27, 2026 5:04 pm | Richard Newitter | Truist Financial | $89.00 | $74.91 | StreetInsider | Lantheus Holdings (LNTH) PT Raised to $89 at Truist Securities |
| December 18, 2025 2:12 pm | — | Truist Financial | $82.00 | $65.35 | TheFly | Lantheus price target raised to $82 from $80 at Truist |
| December 17, 2025 11:58 am | — | Mizuho Securities | $72.00 | $65.17 | TheFly | Lantheus price target raised to $72 from $60 at Mizuho |
| December 11, 2025 9:32 pm | Richard Newitter | Truist Financial | $80.00 | $63.09 | TheFly | Lantheus upgraded to Buy at Truist on profit re-acceleration prospects |
| October 8, 2025 8:29 am | — | Goldman Sachs | $77.00 | $51.84 | TheFly | Lantheus downgraded to Neutral from Buy at Goldman Sachs |
| August 11, 2025 8:26 pm | Richard Newitter | Truist Financial | $63.00 | $56.07 | TheFly | Lantheus downgraded to Hold from Buy at Truist |
| December 18, 2024 9:26 am | Paul Choi | Goldman Sachs | $143.00 | $91.15 | TheFly | Lantheus initiated with a Buy at Goldman Sachs |
Latest News for LNTH
Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH - Get Free Report) have received an average rating of "Moderate Buy" from the eleven research firms that are currently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average
Lantheus Holdings faces a three-month FDA PDUFA extension for OCTEVY, delaying potential approval and launch to June 2026. OCTEVY's extension is procedural, tied to manufacturing review, not efficacy or safety, and is not expected to impact its clinical adoption pathway. While OCTEVY alone won't restore double-digit growth, it can stabilize near-term revenue and support LNTH's strategic pivot to PET radiodiagnostics.
Lantheus (NASDAQ: LNTH - Get Free Report) and High Tide (NASDAQ: HITI - Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation. Analyst Recommendations This is a summary of current ratings
BEDFORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced today that the U.S. Food and Drug Administration (FDA) has extended its review of the New Drug Application (NDA) for LNTH-2501 (Gallium 68…
Although its adjusted net income dipped, it handily beat analyst expectations on both the top and bottom lines. It also announced a very sensible pivot in its business.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LNTH.
U.S. House Trading
No House trades found for LNTH.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.